Sign in
CompletedPhase 3

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Key facts

Who runs it
Arrowhead Pharmaceuticals
Where
Annapolis, Asheboro, Beavercreek, Beverly Hills, Birmingham, Bountiful, Canoga Park, Chattanooga, Clearwater, Columbus, Elkhart, Fort Mill, Fort Worth, Fremont, Greenville, Horsham, Houston, Huntington Beach, Indianapolis, Jackson, Lawrenceville, Lincoln, Long Beach, Manassas, Metairie, Mobile, Morristown, New York, Newport, Norfolk, North Miami, Oklahoma City, Overland Park, Oxnard, Philadelphia, Riverhead, Roanoke, Sarasota, South Bend, St. George, Sugar Hill, Sugar Land, The Bronx, Tomball, Topeka, Victoria, and Wilmington, United StatesSee the 50 sitesAlso in 15 other countries, 101 sites
Status
Completed
Phase
Phase 3
People taking part
311 people enrolled
Started
23 Jul 2024
Ended
10 Sept 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Plozasiran Injection
  • Placebo
Record updated
9 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Established diagnosis of severe hypertriglyceridemia (SHTG) and prior documented evidence (medical history) of fasting TG levels of ≥500 mg/dL (≥5.65 mmol/L)
  • Mean fasting TG level ≥500 mg/dL (≥5.65 mmol/L) collected at 2 separate and consecutive visits at least 7 days apart and no more than 17 days apart during the screening period
  • Fasting low density lipoprotein-cholesterol (LDL-C) ≤130 mg/dL (≤3.37 mmol/L) at screening
  • Screening HbA1C ≤9.0%
  • Must be on standard of care lipid-lowering medications per local guidelines (unless documented as intolerant as determined by the Investigator, including an inability to safely administer or re-administer a specific drug because of fear, preference, genetic, clinical, or metabolic considerations, or due to a previous adverse reaction associated with, attributed to, or caused by specific drug)

Who cannot take part

  • Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and/or triglycerides within 365 days before Day 1 (except inclisiran, which is permitted). Administration of investigational drug and inclisiran must be separated by at least 4 weeks
  • Known diagnosis of familial chylomicronemia syndrome (FCS) (type 1 Hyperlipoproteinemia) by documentation of confirmed homozygote or double heterozygote for loss-of-function mutations in type 1- causing genes
  • Use of any other hepatocyte-targeted siRNA or antisense oligonucleotide molecule within 60 days or within 5-half-lives before Day 1 based on plasma pharmacokinetics (PK), whichever is longer (except inclisiran, which is permitted)
  • Body mass index >45kg/m\^2; Note: Additional Inclusion/Exclusion criteria may apply per protocol

Where in United States

Also in 15 other countries, 101 sites

  • Annapolis, MarylandHospital not named in the registry
  • Asheboro, North CarolinaHospital not named in the registry
  • Beavercreek, OhioHospital not named in the registry
  • Beverly Hills, CaliforniaHospital not named in the registry
  • Birmingham, AlabamaHospital not named in the registry
  • Bountiful, UtahHospital not named in the registry
  • Canoga Park, CaliforniaHospital not named in the registry
  • Chattanooga, TennesseeHospital not named in the registry
  • Clearwater, FloridaHospital not named in the registry
  • Columbus, OhioHospital not named in the registry
  • Elkhart, IndianaHospital not named in the registry
  • Fort Mill, South CarolinaHospital not named in the registry
  • Fort Worth, TexasHospital not named in the registry
  • Fremont, NebraskaHospital not named in the registry
  • Greenville, South CarolinaHospital not named in the registry
  • Horsham, PennsylvaniaHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Huntington Beach, CaliforniaHospital not named in the registry
  • Indianapolis, IndianaHospital not named in the registry
  • Jackson, MississippiHospital not named in the registry
  • Lawrenceville, GeorgiaHospital not named in the registry
  • Lincoln, CaliforniaHospital not named in the registry
  • Long Beach, CaliforniaHospital not named in the registry
  • Manassas, VirginiaHospital not named in the registry
  • Metairie, LouisianaHospital not named in the registry
  • Mobile, AlabamaHospital not named in the registry
  • Morristown, New JerseyHospital not named in the registry
  • New YorkHospital not named in the registry
  • Newport, PennsylvaniaHospital not named in the registry
  • Norfolk, NebraskaHospital not named in the registry
  • North Miami, FloridaHospital not named in the registry
  • Oklahoma City, OklahomaHospital not named in the registry
  • Overland Park, KansasHospital not named in the registry
  • Oxnard, CaliforniaHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Riverhead, New YorkHospital not named in the registry
  • Roanoke, VirginiaHospital not named in the registry
  • Sarasota, FloridaHospital not named in the registry
  • South Bend, IndianaHospital not named in the registry
  • St. George, UtahHospital not named in the registry
  • Sugar Hill, GeorgiaHospital not named in the registry
  • Sugar Land, TexasHospital not named in the registry
  • The Bronx, New YorkHospital not named in the registry
  • Tomball, TexasHospital not named in the registry
  • Topeka, KansasHospital not named in the registry
  • Victoria, TexasHospital not named in the registry
  • Wilmington, North CarolinaHospital not named in the registry

About the trial

What the trial wants to find out

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

The 2 groups in the trial

  • Plozasiran InjectionTreatment being tested

    4 doses of plozasiran (ARO-APOC3) by subcutaneous (sc) injection

  • PlaceboPlacebo, for comparison

    calculated volume to match active treatment by sc injection

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia
Publications
Record updated
9 October 2026